STEVEN I SHERMAN to Anilides
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Anilides.
Connection Strength
1.560
-
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864.
Score: 0.454
-
A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014 Oct; 24(10):1508-14.
Score: 0.396
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
Score: 0.190
-
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 08; 22(8):1126-1138.
Score: 0.159
-
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46.
Score: 0.093
-
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61.
Score: 0.091
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.079
-
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer. 2022 12 15; 128(24):4203-4212.
Score: 0.044
-
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. 2016; 90(6):339-46.
Score: 0.028
-
Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680.
Score: 0.025